SIMPLIFY is the largest medication-withdrawal study in CF todate, motivated by the increasing availability of effective CFTR-modulator therapyto a majority of the CF population, and is poised to test the hypothesis that thereis no meaningful impact on short-term clinical outcomes or safety associated withdiscontinuation of hypertonic saline or dornase alfa. This evidence concerns the gene CFTR and cystic fibrosis.